Monrovia, CA -- (SBWIRE) -- 01/18/2011 -- Daniel Edelman, Facility Head of the Clinical Molecular Profiling Core at NCI, will give a presentation on “The Clinical Molecular Profiling Core: A New Paradigm in Personalized Cancer Care at the National Cancer Institute”. In this new age of targeted and personalized therapies, oncologists have become acutely aware that each patient and their associated tumor have their own characteristic biological properties; matching the correct treatment to the right patient and tumor appears increasingly important.
Because genetic and epigenetic changes are fundamental to cancer pathogenesis, the Clinical Molecular Profiling Core (CMPC) focuses primarily on genomic technologies. Core scientific staff collaborates with clinical investigators to optimize study design in such matters as specimen type and assay selection, and support data analysis and interpretation. Importantly, the CMPC is also CLIA compliant enabling swift translation of research findings to the clinic and the flexibility to meet the unique clinical needs of NCI investigators.
Daniel Edelman earned his MS in Applied Molecular Biology at the University of MD Baltimore County in 1993 and went on to work as a research associate at the VA Medical Center investigating prion diseases under Dr. Bob Rohwer. From there he became a founding member (1994) of the Molecular Diagnostics Laboratory in the University of MD Medical Center under Dr. Sandy Stass where he helped the nascent lab pass two CAP inspections. Dan received his PhD in Medical Pathology in 2005 and after a short post-doc, moved over to the FDA and worked as a scientific reviewer in the OIVD/CDRH under Dr. Sally Hojvat in the Division of Microbiology Devices. For the last four years Dan has been the facility head of the Clinical Molecular Profiling Core under Dr. Paul Meltzer in the Genetics Branch of the Center for Cancer Research, NCI.
Come and join the discussion at GTCbio`s Molecular Diagnostics Conference to be held in Philadelphia, PA on March 7-8, 2011. Network with colleagues in academia, industry, and healthcare to share and learn about the latest technologies and novel discoveries in the diagnostics field. Gain insight into the issues and challenges facing the healthcare industry and hear success stories from industry leaders.
Presenting organizations include Merck, Genentech, Illumina, Quest Diagnostics, On-Q-Ity, OncoVista, Caprion Proteomics and other leaders in the diagnostics industry. For more information, visit www.gtcbio.com